Lupin shares rise 1%; company launches generic version of kidney disorder treatment drug in the US

The stock was trading in the green after the pharma major said it has launched the generic version of Tolvaptan tablets used to slow kidney function decline in the US market, following the recent approval received from the country's health regulator.

The company has launched Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg in the US after receiving the approval from the US Food and Drug Administration (USFDA).

"Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity," Lupin said in a statement.

Tolvaptan tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, Ltd, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), it added.

Lupin CEO Vinita Gupta said the launch of Tolvaptan Tablets in the US will provide ADPKD patients with increased access to high-quality treatment options.

In April 2025, Lupin said it acquired UK-based Renascience Pharma for 12.3 million pounds (around ₹135 crore).

Lupin Healthcare (UK) Ltd, a wholly owned subsidiary of the Mumbai-based drug maker, is acquiring a 100% stake in Renascience, which supplies products in the UK.

With the acquisition, Lupin Healthcare (UK) Limited gains full ownership of Renascience, which, going forward, will trade as its subsidiary, Lupin Ltd said in a statement.

Renascience is the sole supplier of branded injectable cephalosporins for infectious diseases, a topical treatment for ear pain, and a branded quinazoline-like diuretic for cardiovascular and renal indications in the UK market.

Before this, in March this year, the drug company said its board had approved the transfer of its API R&D division to a wholly owned subsidiary on a slump sale basis.

The company's board has also approved a modification to an earlier slump sale transaction by including an additional brand as part of the transfer of OTC business to LCHL on a going-concern basis, the drug maker said in a regulatory filing.